

JAN 12 2007

Appl. No. 10/688,100
Supplemental Amendment
Page 6 of 7

Attorney Docket No.: 08321-0082-DI2

REMARKS

Claims 1, 2, 4, 9, 12-15, 17 and 19-22 are pending in the application upon entry of the herein amendment.

Applicants thank Examiner for the courtesy of the telephone conference of January 11, 2007 with the undersigned attorney. Examiner indicated that the application was allowable except for the disposition of the non-elected claims. Examiner agreed to the rejoinder of the invention of Group II with the elected group and the conversion of claims 2 and 4 from withdrawn to active status. The amendment to claim 1, resulting in the combination of claim 8 into claim 1, was also discussed. The claims drawn to non-elected inventions have been cancelled herein without prejudice to the filing of one or more divisional applications.

An error has been corrected in the Sequence Listing, SEQ ID NO:1. The fourth (Ile) and fifth (Lys) amino acids were inadvertently transposed as "Lys-Ile" in preparing the Sequence Listing. The specification, page 8, line 32 (the sequence "A A L I K...") provides support for the correction.

A paper copy of the amended Sequence Listing is enclosed herewith. The amended computer readable form had been filed on even date herewith via U.S. Express Mail, under cover of a paper entitled "Transmittal of Sequence Listing Computer Readable Form and Statement Under 37 C.F.R. 1.821." The latter contains the appropriate averments in support of the Sequence Listing amendment.

Conclusion


It is believed that all claims remaining in the application are in condition for allowance. An early and favorable action toward that end is therefore respectfully and earnestly solicited.

Appl. No. 10/688,100
Supplemental Amendment
Page 7 of 7

Attorney Docket No.: 08321-0082-D12

Respectfully submitted,

HUI ZHANG, *et al.*



DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP.
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
(215) 988-3312 - phone
(215) 988-2757 - Fax
Attorney for the Applicants

8321-82-DI2.TXT

SEQUENCE LISTING

<110> ZHANG, Hui
POMERANTZ, Roger
YANG, Bin

<120> Multimerization of HIV-1 VIF Protein as
a Therapeutic Target

<130> 08321-0082 DI2

<140> US 10/688,100

<141> 2003-10-17

<150> US 60/282,270

<151> 2001-04-06

<150> US 10/118,575

<151> 2002-04-08

<160> 26

<170> FastSEQ for windows Version 4.0

<210> 1

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Fragment of vif protein sequence

<400> 1

Ala Ala Leu Ile Lys Pro Lys Gln Ile Lys Pro Pro Leu Pro
1 5 10

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Fragment of vif protein sequence

<400> 2

Asp Tyr Lys Asp Asp Asp Asp Lys
1 5

<210> 3

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Fragment of c-Myc protein sequence

<400> 3

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu
1 5 10

<210> 4

<211> 7

<212> PRT

Page 1

8321-82-DI2.TXT

<213> Artificial Sequence

<220>

<223> Fragment of vif protein sequence

<400> 4

Ser Leu Gln Tyr Leu Ala Leu
1 5

<210> 5

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide containing PXP motif

<400> 5

Ser Asn Phe Ala Ser Ile Thr Thr Pro Arg Pro His
1 5 10

<210> 6

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide containing PXP motif

<400> 6

Trp Pro Thr Asn Pro Thr Thr Val Pro Val Pro Ser
1 5 10

<210> 7

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide containing PXP motif

<400> 7

Leu Thr Ser Asp Thr Tyr Phe Leu Pro Val Pro Ala
1 5 10

<210> 8

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide containing PXP motif

<400> 8

Ser Leu His Trp Pro val Ser His Pro Pro Pro Pro
1 5 10

<210> 9

<211> 12

<212> PRT

<213> Artificial Sequence

8321-82-DI2.TXT

<220>

<223> Synthetic peptide containing PXP motif

<400> 9

Ser Val Ser Val Gly Met Lys Pro Ser Pro Arg Pro
1 5 10

<210> 10

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide containing PXP motif

<400> 10

Trp His Ser Gln Arg Leu Ser Pro Val Pro Pro Ala
1 5 10

<210> 11

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide containing PXP motif

<400> 11

Ser Asn Gln Gly Gly Ser Pro Leu Pro Arg Ser Val
1 5 10

<210> 12

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide containing PXP motif

<400> 12

Ser Glu Pro His Leu Pro Phe Pro Val Leu Pro His
1 5 10

<210> 13

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide containing PXP motif

<400> 13

Leu Pro Leu Pro Ala Pro Ser Phe His Arg Thr Thr
1 5 10

<210> 14

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide containing PXP motif

Page 3

8321-82-DI2.TXT

<400> 14
Tyr Pro Leu Pro His Pro Met Trp Ser Met Leu Pro
1 5 10

<210> 15
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide containing PXP motif

<400> 15
Thr Met Thr Pro Pro Pro Thr Ser Val Arg Gly Thr
1 5 10

<210> 16
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide containing PXP motif

<400> 16
Thr Pro Leu Pro Thr Ile Arg Gly Asp Thr Gly Thr
1 5 10

<210> 17
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide containing PXP motif

<400> 17
Gly Pro Pro Pro His His Arg Asp Tyr His Gly Pro
1 5 10

<210> 18
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide containing PXP motif

<400> 18
Tyr Pro Ala Pro Ile Lys Val Leu Leu Pro Asn Ser
1 5 10

<210> 19
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide containing PXP motif

<400> 19

8321-82-DI2.TXT

Ser Pro Tyr Pro Met Ala Leu Phe Pro Leu His Asn
1 5 10

<210> 20
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide containing PXP motif

<400> 20
Ser Pro Tyr Pro Ser Trp Ser Thr Pro Ala Gly Arg
1 5 10

<210> 21
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Fragment of vif

<400> 21
Lys Pro Lys Lys Ile Lys Pro Pro Leu Pro Ser Val
1 5 10

<210> 22
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Fragment of vif

<400> 22
Pro Pro Leu Pro Ser Val Thr Lys Leu Thr Glu Asp Arg Trp Asn
1 5 10 15

<210> 23
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Fragment of vif

<400> 23
Lys Lys Ile Lys Pro Pro Leu Pro Ser Val Thr Lys Leu Thr Glu
1 5 10 15

<210> 24
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Fragment of vif

<400> 24
Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly His Ile Val Ser Pro
1 5 10 15

Page 5

8321-82-DI2.TXT

<210> 25
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Fragment of vif protein

<400> 25
Pro Pro Leu Pro
1

<210> 26
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Fragment of vif protein

<400> 26
Lys val Gly Ser Leu Gln Tyr Leu Ala Leu Ala Ala Leu Ile Thr Pro
1 5 10 15
Lys Lys Ile Lys Pro Pro Leu Pro Ser Val Thr Lys Leu Thr Glu
20 25 30